Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria
22/09/2026 13:54
BRIEF-Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated VRTX.O:
VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DISEASE (AMKD) AND COMPLETION OF ENROLLMENT IN THE PHASE 2/3 AMPLITUDE TRIAL
VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -42.7% AT WEEK 13 IN AMKD WITH MODEST PROTEINURIA
VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -17.3% AT WEEK 13 IN AMKD WITH TYPE 2 DIABETES
VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN GENERALLY SAFE AND WELL TOLERATED IN BOTH AMKD COHORTS
Source text: ID:nBw7hv65ma
Further company coverage: VRTX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria